Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection

被引：30

作者：

Yatim, Nader ^{[1
,2
]}

Boussier, Jeremy ^{[3
]}

Tetu, Pauline ^{[2
]}

Smith, Nikaia ^{[1
]}

Bruel, Timothee ^{[4
,5
]}

Charbit, Bruno ^{[6
]}

Barnabei, Laura ^{[7
]}

Corneau, Aurelien ^{[8
]}

Da Meda, Laetitia ^{[2
]}

Allayous, Clara ^{[2
]}

Baroudjian, Barouyr ^{[2
]}

Jebali, Majdi ^{[2
]}

Herms, Florian ^{[2
]}

Grzelak, Ludivine ^{[4
]}

Staropoli, Isabelle ^{[4
]}

Calmettes, Vincent ^{[9
]}

Hadjadj, Jerome ^{[7
,10
]}

Peyrony, Olivier ^{[11
]}

Cassius, Charles ^{[2
]}

LeGoff, Jerome ^{[12
]}

Kramkimel, Nora ^{[9
]}

Aractingi, Selim ^{[9
]}

Fontes, Magnus ^{[13
]}

Blanc, Catherine ^{[8
]}

Rieux-Laucat, Frederic ^{[7
]}

Schwartz, Olivier ^{[4
,5
]}

Terrier, Benjamin ^{[10
]}

Duffy, Darragh ^{[1
,6
]}

Lebbe, Celeste ^{[2
]}

机构：

[1] Inst Pasteur, Dept Immunol, Translat Immunol Lab, F-75015 Paris, France

[2] Univ Paris, Hop St Louis, AP HP, DMU ICARE,INSERM U 976,Dermatol Dept, Paris, France

[3] Sorbonne Univ, Hop St Antoine, AP HP, F-75012 Paris, France

[4] CNRS, Inst Pasteur, Dept Virol, Virus & Immun Unit,UMR 3569, Paris, France

[5] Vaccine Res Inst, Creteil, France

[6] Inst Pasteur, Cytometry & Biomarkers UTechS, CRT, F-75015 Paris, France

[7] Univ Paris, INSERM, Lab Immunogenet Pediatr Autoimmune Dis, Imagine Inst,UMR 1163, F-75015 Paris, France

[8] Sorbonne Univ, Fac Med, Plateforme Cytometrie Pitie Salpetriere CyPS, PASS,UMS037, F-75013 Paris, France

[9] Univ Paris, Hop Cochin, AP HP, Dept Dermatol, Paris, France

[10] Univ Paris, Hop Cochin, AP HP, Ctr APHP CUP,Dept Internal Med,Natl Referral Ctr, F-75014 Paris, France

[11] Hop St Louis, AP HP, Emergency Dept, Paris, France

[12] Univ Paris, Hop St Louis, AP HP, Equipe INSIGHT,U976,Virol,INSERM, F-75010 Paris, France

[13] Inst Roche, Boulogne, France

来源：

SCIENCE ADVANCES | 2021年 / 7卷 / 34期

关键词：

COVID-19; CANCER; SEPSIS; SAFETY;

D O I：

10.1126/sciadv.abg4081

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 and investigated their transcriptomic, proteomic, and cellular profiles. We found that ICI treatment was not associated with severe COVID-19 and did not alter the induction of inflammatory and type I interferon responses. In-depth phenotyping demonstrated expansion of CD8 effector memory T cells, enhanced T cell activation, and impaired plasmablast induction in ICI-treated COVID-19 patients. The evaluation of specific adaptive immunity in convalescent patients showed higher spike (S), nucleoprotein (N), and membrane (M) antigen-specific T cell responses and similar induction of spike-specific antibody responses. Our findings provide evidence that ICI during COVID-19 enhanced T cell immunity without exacerbating inflammation.

引用

页数：13